A new spherically agglomerated drug composite system with lactose for dry powder inhalation

Advanced Powder Technology

Volumn 14, Issue 2, 2003, Pages 215-229

  Ikegami, Kazuhiko ^a   Kawashima, Yoshiaki ^b   Takeuchi, Hirofumi ^b   Yamamoto, Hiromitsu ^b   Mimura, Kazuki ^a   Momose, Den Ichi ^a   Ouchi, Kiyohisa ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Dry powder inhalation; Inhalation device; Jethaler ; Lactose; Spherical agglomeration; Steroid

Indexed keywords

AGGLOMERATION; CRYSTALS; DRUG PRODUCTS; PARTICLE SIZE ANALYSIS;

DRY POWDER INHALATION;

POWDERS;

EID: 0037256602     PISSN: 09218831     EISSN: None     Source Type: Journal    
DOI: 10.1163/156855203763593994     Document Type: Article

References (16)

1. NHLBI/WHO Workshop Report, Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention. NIH Publ. No. 95-3659 (1995).
2. NIH: NHLBI, Guidelines for the Diagnosis and Management of Asthma. NIH Publ. No. 97-4051 (1997).
3. P. J. Barnes, Inhaled glucocorticids for asthma, N. Engl. J. Med. 332, 868-874 (1995).
4. M. Anderson, N. Lindquvist and C. Sevnsson, Dry powder inhalation of budesonide in allergic rhinitis, Clin. Otolaryngol. 18, 30-33 (1993).
5. S. P. Newman, A. Hollingworth and A. R. Clark, Effect of different modes of inhalation on drug delivery from a dry powder inhaler, Int. J. Pharm. 102, 127-132 (1994).
6. P. J. Davies, G. W. Hanlon and A. J. Molyneux, An investigation into the deposition of inhalation aerosol particles as a function of air flow rate in a modified 'Kirk Lung', J. Pharm. Pharmacol. 28, 908-991 (1976).
7. K. Ikegami, Y. Kawashima, H. Takeuchi, M. Yamamoto, D. Momose, N. Saito and N. Isshiki, In vitro inhalation behavior of spherically agglomerated steroid particles with carrier lactose, Advanced Powder Technol. 11, 323-332 (2000).
8. T. Hino, T. Serigano, H. Yamamoto, H. Takeuchi, T. Niwa and Y. Kawashima, Particle design of Wogon extract dry powder aerosols with granulation method, Int. J. Pharm. 168, 59-68 (1998).
9. T. Serigano, T. Hino, H. Yamamoto, H. Takeuchi and Y. Kawashima, The design of inhalation dry powder by the surface modification of drug particles, J. Soc. Powder Technol., Japan 33, 559-563 (1996).
10. Y. Kawashima, T. Serigano, T. Hino, H. Yamamoto and H. Takeuchi, A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres, Pharm. Res. 15, 1748-1752 (1998).
11. J. H. Bell, P. S. Hartley and J. S. G. Cox, Dry powder aerosols I: a new powder inhalation device, J. Pharm. Sci. 60, 1559-1564 (1971).
12. C. A. Dunber, A. J. Hickey and P. Holzner, Dispersion and characterization of pharmaceutical dry powder aerosols, KONA 16, 7-45 (1998).
13. R. N. Dalby, A. J. Hickey and S. L. Tiano, Medical devices for the delivery of therapeutic aerosol to the lungs, in: Inhalation Aerosols: Physical and Biological Basis for Therapy, A. J. Hickey (Ed.), pp. 449-472. Marcel Dekker, New York (1996).
14. K. Ikegami, Y. Kawashima, H. Takeuchi, M. Yamamoto, D. Momose, K. Ouchi and N. Isshiki, Primary crystal growth during spherical agglomeration in liquid: designing an ideal dry powder inhalation system, Powder Technol. 126, 266-274 (2002).
15. K. Morishima, Y. Kawashima, Y. Kawashima, H. Takeuchi, T. Niwa and T. Hino, Micrometrics characteristics and agglomeration mechanisms in the spherical crystallization of bucillamine by the spherical agglomeration and the emulsion solvent diffusion methods, Powder Technol. 76, 57-64 (1993).
16. European Pharmacopoeia, 3rd edn, Suppl., Preparations for Inhalation, pp. 1657-1661. Council of Europe Publishing, Strasbourg (2001).